Ignite Creation Date:
2024-05-05 @ 10:23 PM
Last Modification Date:
2024-10-26 @ 10:18 AM
Study NCT ID:
NCT01098877
Status:
COMPLETED
Last Update Posted:
2010-10-13
First Post:
2010-03-26
Brief Title:
First In Human Study Of Increasing Oral Doses Of PF-04634817
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
A Double Blind Randomized Placebo Controlled Dose Escalation Study To Investigate The Pharmacokinetics In The Fed And Fasted State Safety And Toleration Of Single Oral Doses Of PF-04634817 In Healthy Volunteers
Status:
COMPLETED
Status Verified Date:
2010-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The study will evaluate the hypothesis that at doses and plasma concentrations which affect pharmacodynamic markers of activity at the chemokine receptors CCR2 and CCR5 the compound is safe and well tolerated It will also evaluate the hypothesis that the pharmacokinetic profile is robust and consistent with a once or twice a day therapeutic administration
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None